Abstract
Determinants of differentiation and apoptosis in myelomonocytic leukemia cells (U937) exposed to the novel hybrid polar compound SAHA (suberoylanilide hydroxamic acid) have been examined. In contrast to hexamethylenbisacetamide (HMBA), SAHA-related maturation was limited and accompanied by marked cytoxicity. SAHA-mediated apoptosis occurred within the G0G1 and S phase populations, and was associated with decreased mitochondrial membrane potential, caspase-3 activation, PARP degradation, hypophosphorylation/cleavage of pRB, and down-regulation of c-Myc, c-Myb, and B-Myb. Enforced expression of Bcl-2 or Bcl-xL inhibited SAHA-induced apoptosis, but only modestly potentiated differentiation. While SAHA induced the cyclin-dependent kinase inhibitor p21CIP1, antisense ablation of this CDKI increased, rather than decreased, SAHA-related lethality. In contrast, conditional expression of wild-type p53 failed to modify SAHA actions, but markedly potentiated HMBA-induced apoptosis. Finally, SAHA modestly increased expression/activation of the stress-activated protein kinase (SAPK/JNK); moreover, SAHA-related lethality was partially attenuated by a dominant-negative c-Jun mutant protein (TAM67). SAHA did not stimulate mitogen-activated protein kinase (MAPK), nor was lethality diminished by the specific MEK/MAPK inhibitor PD98059. These findings indicate that SAHA potently induces apoptosis in human leukemia cells via a pathway that is p53-independent but at least partially regulated by Bcl-2/Bcl-xL, p21CIP1, and the c-Jun/AP-1 signaling cascade.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- ERK:
-
extracellular receptor kinase
- HMBA:
-
hexamethy-lenebisacetamide
- JNK:
-
Jun N-terminal kinase
- MAPK:
-
mitogen-activated protein kinase
- PMA:
-
phorbol myristate acetate
- SAHA:
-
suberoylanilide hydroxamic acid
References
Andreef M, Stone R, Michaeli J, Young CW, Tong W, Sogoloff H, Ervin T, Kufe D, Rifkind RA and Marks PA. . 1992 Blood 80: 2604–2609.
Archer SY, Meng S, Shei A and Hodin RA. . 1998 Proc. Natl. Acad. Sci. USA 95: 6791–6796.
Brown PH, Chen TK and Birrer MJ. . 1994 Oncogene 9: 791–799.
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B. . 1998 Science 282: 1497–1501.
Collins SJ, Gallo RC and Gallegher RE. . 1977 Nature 270: 347–349.
Dangond F and Gullans SR. . 1998 Biochem. Biophys. Res. Commun. 247: 833–837.
de Vente J, Kiley S, Garris T, Bryant W, Hooker J, Posekany K, Parker P, Cook P, Fletcher D and Ways DK. . 1995 Cell Growth Diff. 6: 371–382.
Dong Z, Crawford HC, Lavrovsky V, Taub D, Watts R, Matrisian LM and Colburn NH. . 1997 Mol. Carcinogenesis 19: 204–212.
Dunaef JL, Stober BE, Guha S, Khavari PA, Alin K, Luban J, Begemann M, Brabtree GR and Goff SP. . 1994 Cell 79: 119–130.
Ehinger M, Bergh G, Olofsson T, Baldetorp B, Olsson I and Gullberg U. . 1996 Blood 87: 1064–1074.
Franklin CC and Kraft AS. . 1995 Oncogene 11: 2365–2374.
Gervais JL, Seth P and Zhang H. . 1998 J. Biol. Chem. 273: 19207–19212.
Grant S, Freemerman AJ, Martin H, Turner AJ, Birrer MJ and Jarvis WD. . 1996a Cell Growth Diff. 7: 603–613.
Grant S, Turner AJ, Freemerman AJ, Wang Z, Kramer L and Jarvis WD. . 1996b Exp. Cell Res. 228: 65–75.
Hass R, Pfannkuche H-J, Kharbanda S, Gunji H, Meyer G, Harmann A, Hidaka H, Resch K, Kufe D and Goppelt-Strube M. . 1991 Cell Growth Diff. 2: 541–548.
Jiang H, Lin J, Su Z, Collart FR, Huberman E and Fisher PB. . 1994 Oncogene 9: 3397–3406.
Kharbanda S, Saleem A, Emoto Y, Stone R, Rapp U and Kufe D. . 1994 J. Biol. Chem. 269: 872–878.
Martin SJ, Bradley JG and Cotter TG. . 1990 Clin. Exp. Immunol. 79: 448–453.
McBain JA, Eastman A, Nobel CS and Mueller GC. . 1997 Biochem. Pharmacol. 53: 1357–1368.
Medina V, Edmonds B, Young GP, James R, Appleton S and Zalewski PD. . 1997 Cancer Res. 57: 3697–3707.
Michalovitz D, Halevy O and Oren M. . 1990 Cell 62: 671–680.
Naumovski L and Cleary ML. . 1994 Blood 83: 2261–2267.
Ogryzko VV, Hirai TH, Russanova VR, Barbie DA and Howard BH. . 1996 Mol. Cell Biol. 16: 5210–5218.
Ohta H, Sweeney EA, Masamune A, Yatomi Y, Hakamori S and Igarashi Y. . 1995 Cancer Res. 55: 691–697.
Raff MC. . 1992 Nature 356: 397–400.
Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA and Marks PA. . 1996 Proc. Natl. Acad. Sci. USA 93: 5705–5708.
Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA and Marks PA. . 1998 Proc. Natl. Acad. Sci. USA 95: 3003–3007.
Salminen A, Tapiola T, Korhonen P and Suuronen T. . 1998 Mol. Brain Res. 61: 203–206.
Selvakumaran M, Reed JC, Liebermann D and Hoffman B. . 1994 Blood 84: 1036–1042.
Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. . 1994 Oncogene 9: 3389–3396.
Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Takaku F, Yazaki Y and Hirai H. . 1992 Blood 79: 2378–2383.
Sundstrom C and Nilsson K. . 1976 Int. J. Cancer 17: 565–577.
Tang HY, Zhao K, Pizzolato JF, Fonarev M, Langer JC and Manfredi JJ. . 1998 J. Biol. Chem. 273: 29156–29163.
Thompson MA, Rosenthal MA, Ellis SL, Friend AJ, Zorbas MI, Whitehead RH and Ramsay RG. . 1998 Cancer Res. 58: 5168–5175.
Vaziri C, Stice L, Faller DV. . 1998 Cell Growth Diff. 9: 465–474.
Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI. Kyriakis JM, Haimovitz-Friedman A, Fuks Z and Kolesnick RN. . 1996 Nature 380: 75–79.
Vrana JA, Saunders AM, Chellapan SP and Grant S. . 1998 Differentiation 63: 33–42.
Wang J and Walsh K. . 1996 Science 273: 359–361.
Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P and Grant S. . 1997 Mol. Pharm. 52: 1000–1009.
Wang Z, Su Z-Z, Fisher PB, Van Tuyle G, Wang S and Grant S. . 1998 Exp. Cell Res. 244: 105–116.
Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME. . 1995 Science 270: 1326–1331.
Yen A, Roberson MS, Varvayanis S and Lee AT. . 1998 Cancer Res. 58: 3163–3172.
Acknowledgements
We would like to thank E Freeman, A Nambiar, G Schaefer and J-H Chen for their technical assistance. This work was supported by awards CA63753, CA72955, CA77141, CA35675 from the NIH, award 6405-97 from the Leukemia Society of America, and the Chernow Endowment Trust. PB Fisher is the Michael and Stella Chernow Urological Research Scientist.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vrana, J., Decker, R., Johnson, C. et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18, 7016–7025 (1999). https://doi.org/10.1038/sj.onc.1203176
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203176
Keywords
This article is cited by
-
miR-194-5p/BCLAF1 deregulation in AML tumorigenesis
Leukemia (2017)
-
MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis
Cell Death & Disease (2017)
-
Molecular mechanism leading to SAHA-induced autophagy in tumor cells: evidence for a p53-dependent pathway
Cancer Cell International (2016)
-
Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia
Clinical Epigenetics (2015)
-
Selective class IIa HDAC inhibitors: myth or reality
Cellular and Molecular Life Sciences (2015)